Baird Financial Group’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $64.9M | Buy |
2,310,997
+79,753
| +4% | +$2.12M | 0.1% | 145 |
|
|
2025
Q4 | $55.6M | Sell |
2,231,244
-51,099
| -2% | -$1.29M | 0.09% | 164 |
|
|
2025
Q3 | $58.2M | Sell |
2,282,343
-112,286
| -5% | -$2.77M | 0.09% | 163 |
|
|
2025
Q2 | $58M | Sell |
2,394,629
-406,942
| -15% | -$9.49M | 0.1% | 165 |
|
|
2025
Q1 | $71M | Sell |
2,801,571
-188,043
| -6% | -$4.92M | 0.14% | 133 |
|
|
2024
Q4 | $79.3M | Sell |
2,989,614
-339,331
| -10% | -$9.2M | 0.15% | 116 |
|
|
2024
Q3 | $96.3M | Buy |
3,328,945
+126,242
| +4% | +$3.68M | 0.19% | 104 |
|
|
2024
Q2 | $89.6M | Sell |
3,202,703
-3,322,960
| -51% | -$91.5M | 0.19% | 114 |
|
|
2024
Q1 | $181M | Buy |
6,525,663
+383,974
| +6% | +$10.7M | 0.38% | 54 |
|
|
2023
Q4 | $177M | Sell |
6,141,689
-948,812
| -13% | -$28.7M | 0.4% | 50 |
|
|
2023
Q3 | $235M | Sell |
7,090,501
-181,625
| -2% | -$6.42M | 0.64% | 33 |
|
|
2023
Q2 | $267M | Sell |
7,272,126
-1,086,205
| -13% | -$42.3M | 0.7% | 28 |
|
|
2023
Q1 | $341M | Buy |
8,358,331
+199,129
| +2% | +$8.6M | 0.84% | 20 |
|
|
2022
Q4 | $418M | Buy |
8,159,202
+1,253,519
| +18% | +$60.1M | 1.1% | 15 |
|
|
2022
Q3 | $302M | Buy |
6,905,683
+3,062
| +0% | +$149K | 0.89% | 20 |
|
|
2022
Q2 | $362M | Buy |
6,902,621
+37,743
| +0.5% | +$1.92M | 1% | 14 |
|
|
2022
Q1 | $355M | Sell |
6,864,878
-215,719
| -3% | -$11.2M | 0.88% | 20 |
|
|
2021
Q4 | $418M | Buy |
7,080,597
+19,078
| +0.3% | +$945K | 0.98% | 15 |
|
|
2021
Q3 | $304M | Buy |
7,061,519
+186,335
| +3% | +$8.25M | 0.78% | 19 |
|
|
2021
Q2 | $269M | Buy |
6,875,184
+70,697
| +1% | +$2.75M | 0.7% | 26 |
|
|
2021
Q1 | $247M | Buy |
6,804,487
+176,750
| +3% | +$6.28M | 0.69% | 24 |
|
|
2020
Q4 | $244M | Sell |
6,627,737
-65,785
| -1% | -$2.41M | 0.73% | 21 |
|
|
2020
Q3 | $233M | Buy |
6,693,522
+167,843
| +3% | +$5.88M | 0.8% | 22 |
|
|
2020
Q2 | $202M | Buy |
6,525,679
+425,282
| +7% | +$14.4M | 0.76% | 23 |
|
|
2020
Q1 | $189M | Buy |
6,100,397
+679,229
| +13% | +$23.1M | 0.86% | 18 |
|
|
2019
Q4 | $202M | Sell |
5,421,168
-29,939
| -0.5% | -$1.07M | 0.72% | 21 |
|
|
2019
Q3 | $186M | Sell |
5,451,107
-214,052
| -4% | -$7.78M | 0.73% | 22 |
|
|
2019
Q2 | $233M | Buy |
5,665,159
+3,661,507
| +183% | +$145M | 0.91% | 18 |
|
|
2019
Q1 | $80.7M | Buy |
2,003,652
+242,586
| +14% | +$9.72M | 0.47% | 45 |
|
|
2018
Q4 | $72.9M | Buy |
1,761,066
+74,525
| +4% | +$3.09M | 0.5% | 39 |
|
|
2018
Q3 | $70.8M | Sell |
1,686,541
-45,254
| -3% | -$1.74M | 0.44% | 43 |
|
|
2018
Q2 | $59.6M | Sell |
1,731,795
-144,291
| -8% | -$4.93M | 0.4% | 51 |
|
|
2018
Q1 | $63.2M | Buy |
1,876,086
+76,564
| +4% | +$2.63M | 0.44% | 47 |
|
|
2017
Q4 | $61.8M | Buy |
1,799,522
+65,087
| +4% | +$2.22M | 0.44% | 47 |
|
|
2017
Q3 | $58.7M | Sell |
1,734,435
-37,002
| -2% | -$1.19M | 0.44% | 45 |
|
|
2017
Q2 | $56.5M | Buy |
1,771,437
+116,777
| +7% | +$3.68M | 0.44% | 44 |
|
|
2017
Q1 | $53.7M | Buy |
1,654,660
+19,695
| +1% | +$621K | 0.43% | 42 |
|
|
2016
Q4 | $50.4M | Buy |
1,634,965
+153,638
| +10% | +$4.69M | 0.44% | 42 |
|
|
2016
Q3 | $47.6M | Buy |
1,481,327
+72,889
| +5% | +$2.44M | 0.43% | 58 |
|
|
2016
Q2 | $47.7M | Sell |
1,408,438
-11,278
| -0.8% | -$360K | 0.44% | 59 |
|
|
2016
Q1 | $39.9M | Buy |
1,419,716
+176,909
| +14% | +$5.05M | 0.38% | 70 |
|
|
2015
Q4 | $38.1M | Buy |
1,242,807
+17,126
| +1% | +$539K | 0.38% | 64 |
|
|
2015
Q3 | $36.5M | Buy |
1,225,681
+24,762
| +2% | +$794K | 0.39% | 69 |
|
|
2015
Q2 | $38.2M | Buy |
+1,200,919
| New | +$39.1M | 0.38% | 82 |
|
Other funds holding PFE
VCM
VPM
Baird Financial Group's PFE Position: Q1 2026 in Review
Baird Financial Group increased its Pfizer (PFE) stake by 3.6% in Q1 2026, buying an estimated $2.12M and bringing the position to 2,310,997 shares worth $64.9M. The position accounts for 0.1% of the portfolio, ranked #145.
Baird Financial Group first reported a position in PFE in Q2 2015 and has held it in 44 quarters since. The position peaked at $418M in Q4 2021. 2,935 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- Baird Financial Group held 2,310,997 shares of Pfizer worth $64.9M as of Q1 2026.
- Baird Financial Group bought 79,753 Pfizer shares in Q1 2026, an estimated $2.12M.
- Pfizer made up 0.1% of Baird Financial Group's portfolio in Q1 2026, its #145 holding.
- Baird Financial Group first reported a position in Pfizer in Q2 2015 and has held it in 44 quarters since.
- Baird Financial Group's Pfizer position peaked at $418M in Q4 2021.
- 2,935 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on Baird Financial Group's 13F filing for Q1 2026, filed 14 May 2026.